B-CELL LYMPHOMA

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This study tests a combination of two drugs, zanubrutinib and rituximab, for people with B-cell lymphoma who develop a severe immune overreaction called hemophagocytic lymphohistiocytosis (HLH). The trial will enroll 40 participants and aims to see how well the treatment controls…

This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…

This early-stage trial is testing a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better attack cancer cells. The study will enroll 30 par…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This study tests two drugs, mosunetuzumab and lenalidomide, as the first treatment for people with follicular or marginal zone lymphoma. About 52 adults will receive the drugs in cycles, with the dose adjusted based on how well the cancer responds. The goal is to see how many pat…

This study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not responded to standard treatments. Participants receive their o…

This study tests a combination of two drugs, rituximab and zanubrutinib, in people with untreated follicular lymphoma or marginal zone lymphoma. The goal is to see if the combination is safe and effective at shrinking or controlling the cancer. About 43 participants will receive …

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…

This early-phase trial tests an experimental daily pill, LP-168, in about 200 adults whose B-cell lymphoma has returned or not responded to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors …

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior therapy. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main goal …

This early-stage study tests a new type of immune cell therapy (BAFF-R CAR-T) in 30 adults with a specific form of B-cell lymphoma that has come back or not responded to treatment. The main goal is to see if the treatment is safe and tolerable. Participants receive a single infus…

This study tests a combination of two drugs, pembrolizumab and all-trans retinoic acid (ATRA), in adults with Hodgkin or B-Non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the combo is safe and can shrink tumors. About 24 particip…

This study is for people with a type of blood cancer called B-cell lymphoma that has returned or not improved with standard treatments. Researchers are testing a new gene therapy (LCAR02) that targets a protein called CD19 on cancer cells. Up to 18 adults will receive the treatme…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study is for people whose B-cell cancers (like certain lymphomas) have come back or not responded to treatment. It tests a new drug called BGB-16673, which breaks down a protein that helps cancer grow, combined with other cancer drugs. The goal is to find safe doses and see …

This study tests whether giving two powerful cell therapies together can control large B cell lymphoma that has returned or not responded to first treatment. About 40 adults will receive the drugs axicabtagene ciloleucel and glofitamab. The goal is to manage the disease, not to c…

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus ear…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and certain related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time, i…

This study follows up to 500 children and young adults (up to age 26) with B-cell leukemia or lymphoma who have received immunotherapy like Kymriah or blinatumomab. Researchers will use surveys and medical records to track survival, remission, and unmet needs. No new treatment is…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…